IMpower133: Primary efficacy and safety plus CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)
ANNALS OF ONCOLOGY（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要